The modulation of nAChRs, particularly α7nAChR, has been demonstrated to treat nervous-system disorders, including schizophrenia as well as depression, and neurodegenerative diseases including AD and Parkinson’s disease (Taly et al., 2009; Hoskin et al., 2019). Here, CHRNA7 is linked to depressive disorder.